Mr. Todd Shapiro reports

RED LIGHT HOLLAND SHOWCASES GROWING CLINICAL DEMAND FOR FILAMENT HEALTH'S PEX010 WITH NEW AND REPEAT UNIVERSITY SHIPMENTS

Red Light Holland Corp. has highlighted continued expansion and execution of clinical supply shipments of PEX010, a botanical psilocybin drug candidate developed by Filament Health Corp., to leading Canadian research institutions.

Following its press release dated April 7, 2026, Red Light is highlighting recent accomplishments and continuing momentum, including completed and pending shipments supporting multiple clinical trials.

The company confirms that additional shipments of Filament Health's PEX010 have been delivered to University of Calgary (UCalgary) in support of continuing studies. These represent second shipments for:

• Mechanisms supporting psilocybin-assisted psychotherapy for alcohol use disorder: a randomized, controlled clinical trial;
• A randomized double-blinded, controlled trial for the treatment of persistent postconcussion symptoms with psilocybin-assisted therapy: a safety and feasibility trial.

Red Light is also highlighting coming new first-time shipments of Filament Health's PEX010 scheduled for next week to:

• University of British Columbia (UBC) -- psilocybin-assisted therapy for treatment-resistant depression in bipolar II disorder: a randomized controlled trial;
• UCalgary -- the role of the stress experience in supporting positive effects following psilocybin: a randomized, controlled clinical trial using the cortisol synthesis inhibitor metyrapone in healthy adults.

These continued shipments reflect growing demand for pharmaceutical-grade, naturally derived psilocybin and reinforce the expanding role of Filament Health's PEX010 in supporting academic and clinical research initiatives.

PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical-grade natural psilocybin, supporting more than 70 academic and philanthropic research studies around the world.

Red Light recently announced a definitive arrangement agreement to acquire Filament Health, including its portfolio of 76 issued patents across 15 patent families and its lead drug candidate, PEX010. On March 23, 2026, Filament obtained an interim order from the Supreme Court of British Columbia in connection with the proposed arrangement, as the parties move much closer toward completing the transaction, subject to Filament shareholder approval, final court approval and other customary closing conditions.

About Red Light Holland Corp.

Red Light Holland is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centred on consensual data collection and R&D (research and development) initiatives designed to expand naturally occurring drug development, understanding of psilocybin use, and consumer experiences. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B (business-to-business) and DTC (direct-to-consumer) channels, in compliance with applicable laws.

About Filament Health Corp.

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates.

We seek Safe Harbor.